Pharming Group (PHAR) said Tuesday it expects 2026 revenue in the range of $405 million to $425 million, representing 8% to 13% growth.
Analysts surveyed by FactSet expect $395.1 million.
The company said it expects full-year operating expenses of between $330 million and $335 million.
Pharming Group shares were up 3.9% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.